Basic Information

Common Name
B-hCLDN18.2 MC38
Aliases
SFTA5, SFTPJ
Stock Number
310715
Cell Type/Disease
Colon Carcinoma
Species/Strain
Mus musculus, C57BL/6
NCBI Gene ID

Description

The human CLDN18.2 coding sequence was inserted into the ROSA26 locus in MC38 cells. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 MC38 cells.

Application

B-hCLDN18.2 MC38 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Target strategy

The exogenous promoter and human CLDN18.2 coding sequence was inserted into the ROSA26 locus in murine.

Protein expression analysis

CLDN18.2 expression analysis in B-hCLDN18.2 MC38 cells by flow cytometry. Single cell suspensions from wild-type MC38 and B-hCLDN18.2 MC38 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 MC38 cells but not wild-type MC38 cells. The 1-F6 clone of B-hCLDN18.2 MC38 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCLDN18.2 MC38 cells. B-hCLDN18.2 MC38 cells (5×105) and wild-type MC38 cells (5×105) were subcutaneously implanted into C57BL/6 mice (female, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hCLDN18.2 MC38 cells were able to establish tumors in vivo and can be used for efficacy studies.

In vivo efficacy of anti human CLDN18.2 antibodies

Antitumor activity of anti-human CLDN18.2 antibodies in C57BL/6 mice. (A) Anti human CLDN18.2 antibodies inhibited B-hCLDN18.2 MC38  tumor growth in C57BL/6 mice. B-hCLDN18.2 MC38 were subcutaneously implanted into C57BL/6 mice (n=7). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti-human CLDN18.2  antibody with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human CLDN18.2 antibody was efficacious in controlling tumor growth in C57BL/6 mice, demonstrating that the B-hCLDN18.2 MC38 provide a powerful preclinical model for in vivo evaluation of anti-human CLDN18.2 antibodies. Values are expressed as mean ± SEM.

In vivo efficacy of anti human CLDN18.2-ADC drugs

Antitumor activity of anti human CLDN18.2-ADC drugs in C57BL/6 mice. (A) Anti human CLDN18.2-ADC drugs inhibited B-hCLDN18.2 MC38 tumor growth in C57BL/6 mice. B-hCLDN18.2 MC38 were subcutaneously implanted into C57BL/6 mice(n=6). Mice were grouped when tumor volume reached approximately 100 mm3, at which time they were treated with anti human CLDN18.2-ADC drugs with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti human CLDN18.2-ADC drugs was efficacious in controlling tumor growth in C57BL/6 mice, demonstrating that the B-hCLDN18.2 MC38 provide a powerful preclinical model for in vivo evaluation of anti human CLDN18.2-ADC drugs. Values are expressed as mean ± SEM.

Back to top